Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||DETD-35 + Vemurafenib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DETD-35||DETD-35 is a derivative of plant sesquiterpene lactone that inhibits Mek-Erk signaling and induces reactive oxygen species generation, which may lead to apoptosis in tumor cells (PMID: 27048951).|
|Vemurafenib||Zelboraf||RO5185426|PLX4032||RAF Inhibitor (Pan) 16||Zelboraf (vemurafenib) inhibits BRAF V600E, wild-type BRAF, ARAF, and CRAF (PMID: 20179705), which may result in an inhibition of the MAPK signaling pathway resulting in a reduction of tumor cell proliferation (PMID: 20823850). Zelboraf (vemurafenib) is FDA approved for BRAF V600E-mutant melanoma and for BRAF V600-positive Erdheim-Chester disease (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||melanoma||sensitive||DETD-35 + Vemurafenib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).||27048951|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|